Drug Discovery and Development: Technology in Transition

Front Cover
Churchill Livingstone / Elsevier, 2006 - Medical - 346 pages
0 Reviews
This title is directed primarily toward health care professionals outside the United States. An ideal introduction to the pharmaceutical industry, this book describes the process of bringing a new drug to the marketplace. It explains why, although thousands of compounds show initial promise, only a small handful will be developed for human clinical trials and perhaps only one will become an approved drug. Describing the huge complexities involved, it shows how new molecular understanding and techniques can make the process more targeted and successful.

  • Includes the new molecular techniques of drug design and development.
  • Discusses current therapeutic needs.
  • Covers pharmacoepidemiology and pharmacoeconomics.
  • Edited by Humphrey Rang, who is also known throughout the world as a co-author of the enormously successful and authoritative textbook, Pharmacology, now in its fifth edition.
  • Foreword by Daniel Vasella, CEO, Novartis International.
  • Includes contributors from both the pharmaceutical industry and universities.

From inside the book

What people are saying - Write a review

We haven't found any reviews in the usual places.


introduction 221 22 Drug discovery and development facts
The nature of disease and the purpose of Choosing the project

13 other sections not shown

Other editions - View all

Common terms and phrases

References to this book

About the author (2006)

Dr. Daniel Vasella has been the chairman and CEO of Novartis, one of the world's largest pharmaceutical companies, since it was formed in 1996. A native of Switzerland, he was a practicing physician before joining the industry as a pharmaceutical executive. He spent the first years of his business career in the United States before returning to Switzerland to take up his current position.

Bibliographic information